Appeals ruling a significant legal victory for Edwards, says Wells Fargo Wells Fargo said it views today's appeals court ruling as a significant legal victory for Edwards Lifesciences (EW), noting it's the third favorable court ruling for Edwards in its litigation with Medtronic's (MDT) CoreValve. Wells estimates the upside to Edwards Lifesciences from the litigation could be about $486M after tax, or $4.11 per share. The firm continues to expect both companies to negotiate a settlement which would allow Medtronic to enter the U.S. market once CoreValve receives approval towards the end of 2014. Wells Fargo has an Outperform rating on Edwards Lifesciences.
News For EW;MDT From The Last 14 Days
Check below for free stories on EW;MDT the last two weeks.